Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Acenocoumarol and Proton Pump Inhibitors Interaction: Results from a Prospective, Multicenter Study
*Corresponding Author: Vallès Callol JA, Drug Support Unit, Barcelona Primary Healthcare Area, Catalan Health Institute, Barcelona, Spain, Tel: +34-607074583, Email: javalles.bcn.ics@gencat.catReceived Date: Oct 29, 2019 / Accepted Date: Dec 10, 2019 / Published Date: Dec 20, 2019
Citation: Grau Bartomeu J, Gallardo Martínez LJ, Olona Tabueña N, Moreno Oliver A, Vallès Callol JA (2019) Acenocoumarol and Proton Pump Inhibitors Interaction: Results from a Prospective, Multicenter Study. J Community Med Health Educ 9: 672.
Copyright: © 2019 Garu Bartomeu J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: The interaction between acenocoumarol and omeprazole is described to be possible in different forums even though the evidence shows that both can be prescribed together safely.
Aim: To evaluate the introduction of omeprazole on the effect of acenocoumarol in primary care clinical practice.
Design and setting: Cross-sectional study with prospective follow-up of the patients treated with acenocoumarol for 18 months period in 5 health urban areas.
Method: Association of age, sex, anticoagulant dose, indication and INR values according the use of acenocoumarol and PPI.
Results: Of the 260 patients with acenocoumarol (with 3,280 INR measurements) at the start, 126 (48.5%) had previously been with some PPI (97 took omeprazole, mean INR of 2.43), 134 patients were not taking any PPI at the start of the study. Of the patients not previously treated with a PPI, 52 started with some PPI during the monitoring period; in 47 cases the PPI was omeprazole, 33 (70.2%) of which had an INR within the therapeutic range just before the administration of omeprazole. After the administration of omeprazole, 30 patients (90.9%) remained within the therapeutic range. The mean INR values just before and after the administration of omeprazole were 2.47 and 2.46 respectively (P=0.814).
Conclusion: The addition of omeprazole to patients treated with acenocoumarol did not modify the INR values, reaffirming that there is no drug interaction. Long-term concomitant treatment with acenocoumarol and omeprazole is compatible with the INR measures within the target range.
